Tianjin Ringpu Bio Tech
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, drug preparation, functional additives, and veterinary biological products. The company provides anthelmintics, pet vaccines, ear canal treatment drugs, anesthetic analgesics, antibiotics, antivirals, various internal medicine drugs, as well as disinfectant products, i… Read more
Tianjin Ringpu Bio Tech (300119) - Net Assets
Latest net assets as of September 2025: CN¥5.15 Billion CNY
Based on the latest financial reports, Tianjin Ringpu Bio Tech (300119) has net assets worth CN¥5.15 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.69 Billion) and total liabilities (CN¥2.54 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.15 Billion |
| % of Total Assets | 66.96% |
| Annual Growth Rate | 23.61% |
| 5-Year Change | 82.93% |
| 10-Year Change | 183.07% |
| Growth Volatility | 108.31 |
Tianjin Ringpu Bio Tech - Net Assets Trend (2007–2024)
This chart illustrates how Tianjin Ringpu Bio Tech's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tianjin Ringpu Bio Tech (2007–2024)
The table below shows the annual net assets of Tianjin Ringpu Bio Tech from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.01 Billion | +4.21% |
| 2023-12-31 | CN¥4.80 Billion | +6.75% |
| 2022-12-31 | CN¥4.50 Billion | +4.10% |
| 2021-12-31 | CN¥4.32 Billion | +57.97% |
| 2020-12-31 | CN¥2.74 Billion | +16.12% |
| 2019-12-31 | CN¥2.36 Billion | +4.56% |
| 2018-12-31 | CN¥2.25 Billion | +3.59% |
| 2017-12-31 | CN¥2.18 Billion | +3.36% |
| 2016-12-31 | CN¥2.11 Billion | +19.03% |
| 2015-12-31 | CN¥1.77 Billion | +2.50% |
| 2014-12-31 | CN¥1.73 Billion | +0.32% |
| 2013-12-31 | CN¥1.72 Billion | +8.44% |
| 2012-12-31 | CN¥1.59 Billion | +6.03% |
| 2011-12-31 | CN¥1.50 Billion | +4.86% |
| 2010-12-31 | CN¥1.43 Billion | +465.11% |
| 2009-12-31 | CN¥252.48 Million | +1.00% |
| 2008-12-31 | CN¥249.97 Million | +83.53% |
| 2007-12-31 | CN¥136.21 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tianjin Ringpu Bio Tech's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4141.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.79 Billion | 39.96% |
| Common Stock | CN¥465.85 Million | 10.42% |
| Other Components | CN¥2.22 Billion | 49.62% |
| Total Equity | CN¥4.47 Billion | 100.00% |
Tianjin Ringpu Bio Tech Competitors by Market Cap
The table below lists competitors of Tianjin Ringpu Bio Tech ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beingmate Baby & Child Food Co Ltd
SHE:002570
|
$621.98 Million |
|
Jiangsu Yueda Investment Co Ltd
SHG:600805
|
$622.12 Million |
|
Sinopec Shanghai Petrochemical Company Limited
PINK:SPTJF
|
$622.20 Million |
|
INVENTURUS KNOWLEDGE SO L
NSE:IKS
|
$622.20 Million |
|
Embla Medical hf
CO:EMBLA
|
$621.39 Million |
|
Long Young Electronic (Kunshan) Co. Ltd. A
SHE:301389
|
$621.31 Million |
|
Jiangyin Haida Rubber and Plastic Co Ltd Class A
SHE:300320
|
$621.28 Million |
|
Diös Fastigheter AB (publ)
F:D1F
|
$621.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tianjin Ringpu Bio Tech's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,496,304,113 to 4,469,990,178, a change of -26,313,935 (-0.6%).
- Net income of 300,722,273 contributed positively to equity growth.
- Dividend payments of 215,783,808 reduced retained earnings.
- Share repurchases of 115,072,759 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥300.72 Million | +6.73% |
| Dividends Paid | CN¥215.78 Million | -4.83% |
| Share Repurchases | CN¥115.07 Million | -2.57% |
| Other Changes | CN¥3.82 Million | +0.09% |
| Total Change | CN¥- | -0.59% |
Book Value vs Market Value Analysis
This analysis compares Tianjin Ringpu Bio Tech's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.01x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 44.91x to 2.01x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.44 | CN¥19.56 | x |
| 2008-12-31 | CN¥0.72 | CN¥19.56 | x |
| 2009-12-31 | CN¥0.71 | CN¥19.56 | x |
| 2010-12-31 | CN¥4.36 | CN¥19.56 | x |
| 2011-12-31 | CN¥3.61 | CN¥19.56 | x |
| 2012-12-31 | CN¥3.88 | CN¥19.56 | x |
| 2013-12-31 | CN¥4.14 | CN¥19.56 | x |
| 2014-12-31 | CN¥4.19 | CN¥19.56 | x |
| 2015-12-31 | CN¥4.13 | CN¥19.56 | x |
| 2016-12-31 | CN¥4.83 | CN¥19.56 | x |
| 2017-12-31 | CN¥4.82 | CN¥19.56 | x |
| 2018-12-31 | CN¥4.97 | CN¥19.56 | x |
| 2019-12-31 | CN¥5.34 | CN¥19.56 | x |
| 2020-12-31 | CN¥6.10 | CN¥19.56 | x |
| 2021-12-31 | CN¥8.65 | CN¥19.56 | x |
| 2022-12-31 | CN¥9.02 | CN¥19.56 | x |
| 2023-12-31 | CN¥9.70 | CN¥19.56 | x |
| 2024-12-31 | CN¥9.71 | CN¥19.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tianjin Ringpu Bio Tech utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.73%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.80%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.78x
- Recent ROE (6.73%) is below the historical average (11.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 37.21% | 25.30% | 0.78x | 1.88x | CN¥27.03 Million |
| 2008 | 21.96% | 19.33% | 0.67x | 1.70x | CN¥23.60 Million |
| 2009 | 29.80% | 21.55% | 0.69x | 2.01x | CN¥40.86 Million |
| 2010 | 6.10% | 23.88% | 0.21x | 1.20x | CN¥-52.77 Million |
| 2011 | 8.19% | 19.41% | 0.35x | 1.20x | CN¥-25.20 Million |
| 2012 | 9.71% | 21.95% | 0.37x | 1.21x | CN¥-4.35 Million |
| 2013 | 9.43% | 20.13% | 0.38x | 1.24x | CN¥-9.18 Million |
| 2014 | 1.67% | 4.61% | 0.30x | 1.23x | CN¥-134.50 Million |
| 2015 | 6.86% | 13.91% | 0.34x | 1.46x | CN¥-50.46 Million |
| 2016 | 6.98% | 13.69% | 0.35x | 1.44x | CN¥-57.57 Million |
| 2017 | 5.37% | 10.02% | 0.36x | 1.50x | CN¥-90.29 Million |
| 2018 | 5.92% | 10.00% | 0.40x | 1.49x | CN¥-82.04 Million |
| 2019 | 9.16% | 13.25% | 0.41x | 1.68x | CN¥-17.83 Million |
| 2020 | 16.22% | 19.91% | 0.51x | 1.59x | CN¥152.64 Million |
| 2021 | 10.24% | 20.57% | 0.35x | 1.41x | CN¥9.52 Million |
| 2022 | 8.21% | 16.63% | 0.34x | 1.45x | CN¥-75.45 Million |
| 2023 | 10.09% | 16.74% | 0.41x | 1.47x | CN¥3.96 Million |
| 2024 | 6.73% | 9.80% | 0.39x | 1.78x | CN¥-146.28 Million |
Industry Comparison
This section compares Tianjin Ringpu Bio Tech's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tianjin Ringpu Bio Tech (300119) | CN¥5.15 Billion | 37.21% | 0.49x | $621.64 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |